Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. 2021

Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan.

HER3 belongs to the epidermal growth factor receptor (EGFR) family and is known to form an active heterodimer with other three family members EGFR, HER2, and HER4. HER3 is overexpressed in lung, breast, colon, prostate, and gastric cancers. In the present study, we developed and validated an anti‑HER3 monoclonal antibody (mAb), H3Mab‑17 (IgG2a, kappa), by immunizing mice with HER3‑overexpressed CHO‑K1 cells (CHO/HER3). H3Mab‑17 was found to react specifically with endogenous HER3 in colorectal carcinoma cell lines, using flow cytometry. The KD for H3Mab‑17 in CHO/HER3 and Caco‑2 (a colon cancer cell line) were determined to be 3.0x10‑9 M and 1.5x10‑9 M via flow cytometry, respectively, suggesting high binding affinity of H3Mab‑17 to HER3. Then, we assessed the H3Mab‑17 antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC) against Caco‑2, and evaluated its antitumor capacity in a Caco‑2 xenograft model. In vitro experiments revealed H3Mab‑17 had strongly induced both ADCC and CDC against Caco‑2 cells. In vivo experiments on Caco‑2 xenografts revealed that H3Mab‑17 treatment significantly reduced tumor growth compared with the control mouse IgG. These data indicated that H3Mab‑17 could be a promising treatment option for HER3‑expressing colon cancers.

UI MeSH Term Description Entries
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
April 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
April 2022, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
August 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
September 2016, Cancer letters,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
August 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
March 2019, Biochemistry and biophysics reports,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
August 2020, Experimental and therapeutic medicine,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
April 2024, Acta pharmacologica Sinica,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
December 2020, Biochemistry and biophysics reports,
Teizo Asano, and Tomokazu Ohishi, and Junko Takei, and Takuro Nakamura, and Ren Nanamiya, and Hideki Hosono, and Tomohiro Tanaka, and Masato Sano, and Hiroyuki Harada, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
August 2007, Cancer research,
Copied contents to your clipboard!